Mersana Therapeutics, Inc.
DelistedCIK 1442836fmd_1YX9DMEDQEM9DFDNR1CNBTHQXWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2025, 40 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 10 | 25 | 18 | 11 | 42 | 1 | 0 | 27 | 37 | 40 |
| Research and development | 21 | 32 | 47 | 60 | 55 | 67 | 132 | 173 | 148 | 73 |
| Total operating expenses | 27 | 39 | 57 | 76 | 72 | 89 | 169 | 230 | 217 | 114 |
| Interest expense | – | – | – | 0 | 0 | 0 | 1 | 3 | 4 | 4 |
| Interest and investment income | – | – | 1 | 1 | 2 | 0 | 0 | 3 | 12 | 8 |
| Other non-operating income (expense) | (0) | 0 | 1 | 1 | 2 | 0 | (1) | (0) | 8 | 5 |
| Income before taxes | – | – | – | – | – | – | – | (204) | (172) | (69) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (204) | (172) | (69) |
| Net income | (16) | (14) | (39) | (64) | (28) | (88) | (170) | (204) | (172) | (69) |
| Net income to common shareholders | (16) | (14) | (39) | (64) | (28) | (88) | (170) | (204) | (172) | (69) |